Table 1.

Patient characteristics

Patient #	Age	Diagnosis–stage	Conditioning regimen	Donor type/gender match	GvHD prophylaxis
1	58	PMF–acceleration	FBM	MUD m to m	ATG, CyA, MMF
2	50	AML–1st CR	treo/flud	MUD m to m	ATG, CyA, MTX
3	21	AML–3rd PR	thio/flud	MMUD m to m	everolimus
4	62	CLL–Richter’s transformation	FBM	MUD f to m	ATG, CyA, MTX
5	41	AML–2nd CR	FBM	MRD f to f	CyA, MTX
6	44	AML–1st CR	FBM	MUD m to f	ATG, CyA, MTX
7	54	sAML–1st CR	FTM	MRD m to f	CyA, MTX
8	44	AML–1st CR	FTM	MUD m to f	ATG, tacrolimus, MMF
9	51	FL & CTLC–3rd PR	FTM	MRD f to f	CyA, MTX
10	40	ALL, Ph+–CR	flud/8 Gy TBI	MRD m to m	CyA, MTX
11	49	MM–SD	thio/treo/flud	MUD f to f	tacrolimus, MTX
Median	49

PMF, primary myelofibrosis; (s)AML, (secondary) acute myeloid leukemia; CLL, chronic lymphocytic leukemia; FL, follicular lymphoma; CTLC, cutaneous T cell lymphoma; ALL, acute lymphoblastic leukemia; MM, multiple myeloma; FBM, fludarabine/busulfan/melphalan; FTM, fludarabine/thiotepa/melphalan; treo, treosulfan; flud, fludarabine; thio, thiotepa; TBI, total body irradiation; MRD, matched related donor; MUD, matched unrelated donor; MMUD, mismatch unrelated donor; m, male; f, female; ATG, anti-thymocyte globulin; CyA, cyclosporine; MMF, mycophenolate; MTX, methotrexate